Skip to main content
OpenTrials
Completed

NCT Number: NCT01284608

Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)

This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostatic Cancer Diabetes Mellitus Endocrine System Diseases Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Male Urogenital Diseases Metabolic Diseases Metabolic Syndrome Neoplasms Neoplasms by Site Nutritional and Metabolic Diseases Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Research Site, Albacete, Spain

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment
  • Provision of informed consent prior to conducting any study-related procedure

Exclusion criteria

  • Patient involved in a Clinical Trial

Treatment and study plan

Primary outcomes

  1. Metabolic syndrome

    Time frame: 3 months

  2. Metabolic syndrome

    Time frame: 6 months

  3. Metabolic syndrome

    Time frame: 12 months

  4. Diabetes

    Time frame: 3 months

  5. Diabetes

    Time frame: 6 months

  6. Diabetes

    Time frame: 12 months

Secondary outcomes

  1. Fracture Risk Assessment Tool (FRAx) assessment

    Time frame: 0 and 12 months

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: UROCOR

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Jan 27, 2011
Registry last updated
Dec 24, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.